Post-earnings recap
Reported
Wed, Feb 17, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates significant challenges for 10X Genomics, particularly reflected in the large EPS miss. The stock's 2.54% decline suggests investor concern over the company's current trajectory and lack of guidance for future performance. Without clear direction from management, investors may remain cautious in the near term.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.87 | N/A | -1297.11% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the ongoing market conditions affecting performance. They did not provide a clear outlook for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.